Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in the Netherlands: A multivariate analysis

Clinical Therapeutics

Volumn 19, Issue 4, 1997, Pages 798-810

  Pathiyal, Atul ^a   Hylan, Timothy R ^b   Jones, Judith K ^a   Davtian, David ^a   Sverdlov, Lev ^a   Keyser, Mary ^a  

^a The Degge Group Ltd   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Anxiolytics; Netherlands; Sedative hypnotics; SSRIs

Indexed keywords

ANXIOLYTIC AGENT; FLUOXETINE; HYPNOTIC AGENT; PAROXETINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; DATA BASE; DEPRESSION; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NETHERLANDS; PRESCRIPTION; REGRESSION ANALYSIS; SLEEP DISORDER;

EID: 0030843938     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80103-8     Document Type: Article

References (20)

1. Rascati K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786-790.
2. Navarro R, Valler WE, Spangler M. Anti-depressant utilization in managed care: An evaluation of SSRI use in two HMO settings. Med Interface. 1995;8:114-123.
3. Gregor KJ, Riley JA, Downing DK. Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors. Clin Ther. 1996;18:521-527.
4. Gram LF. Fluoxetine. NEJM. 1994;331: 1354-1361.
5. Tollefson GD. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. 1st ed. Washington, DC: American Psychiatric Press: 1995:161-182.
6. Parkes AJ. Starting SSRI therapy: Its effect on tricyclic and benzodiazepine prescribing. Med J Aust. 1996;164:509. Letter.
7. Beasley CM Jr, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: Activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992;12:328-333.
8. Sheehan D, Dunbar GC, Fuell DL. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull. 1992;28:138-143.
9. Boyer WF, Feighner JP. An overview of paroxetine. J Clin Psychiatry. 1992;53 (Suppl):3-6.
10. DeWilde J, Spiers R, Mertens C, et al. A double-blind comparative, multicenter study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993;87:141-145.
11. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry. 1994;55:394-400.
12. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med. 1994;97(6A):24S-32S.
13. Isacson D, Carsjo K, Haglund B, Smedby B. Psychotropic drug use in a Swedish community: patterns of individual use during 2 years. Soc Sci Med. 1988;27: 263-267.
14. Isacson D, Carsjo K, Bergman U, Blackburn J. Long-term use of benzodiazepines. J Clin Epidemiol. 1992;45:429-436.
15. Isacson D, Bingefors K, Wennberg M, et al. Factors associated with high-quantity prescriptions of benzodiazepines in Sweden. Soc Sci Med. 1993;36:343-351.
16. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994;48:25-40.
17. Kupfer DJ, Reynolds CF. Management of insomnia. NEJM. 1997;336:341-346.
18. Greene WH. Econometric Analysis. 2nd ed. New York: Macmillan; 1994:643-645.
19. Oswald I, Adam K. Effects of paroxetine on sleep. Br J Clin Pharmacol. 1986;22: 97-99.
20. Van der Waals FW, Mohrs J, Foets M. Sex differences among recipients of benzodiazepines in Dutch general practice. Br Med J. 1993;307:363-366.